Tenax Therapeutics Inc (TENX) Actualités

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term...

Current Report Filing (8-k)

0000034956false00000349562023-05-312023-05-31iso4217:USDxbrli:sharesiso4217:USDxbrli:shares   UNITED STATESSECURITIES AND EXCHANGE...

Additional Proxy Soliciting Materials (definitive) (defa14a)

  UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   SCHEDULE 14A INFORMATION Proxy Statement Pursuant to...

Proxy Statement (definitive) (def 14a)

     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   SCHEDULE 14A INFORMATION Proxy Statement...

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   SCHEDULE 14A INFORMATION Proxy Statement...

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Filed pursuant to Rule 424(b)(3) SEC File No. 333- 269363   PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated February 3, 2023)  ...